Levy, Benjamin <br/><br/>
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.  [electronic resource] 

 -  Clinical lung cancer  05 2019 
 - e407-e412 p.  digital 
<br/><br/> Publication Type: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0690 
<br/><br/><label>Standard No.: </label>10.1016/j.cllc.2018.12.022  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Female<br/>Humans<br/>Male<br/>Afatinib--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Squamous Cell--drug therapy<br/>ErbB Receptors--antagonists & inhibitors<br/>Immunotherapy--methods<br/>Lung Neoplasms--drug therapy<br/>Mutation--genetics<br/>Neoplasm Staging<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Survival Analysis<br/>Treatment Outcome<br/>Clinical Trials, Phase II as Topic